Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TAS2R8 | Q9NYW2 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11398860 | 0.89 | GAA (0.74) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL8291275 | 0.87 | GAA (1.00) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL13879567 | 0.86 | GAA (0.59) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL13879489 | 0.85 | GAA (0.58) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL13879582 | 0.82 | GAA (0.56) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL13879423 | 0.82 | GAA (0.56) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL13879403 | 0.81 | GAA (0.56) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL13879474 | 0.80 | MAPT (0.57) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL18399897 | 0.80 | GAA (0.59) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL8819321 | 0.79 | ALDH1A1 (0.78) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | GAA 463/4885CYP1A2 1454/4885CYP3A4 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.